Eton Pharmaceuticals Files 8-K
Ticker: ETON · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1710340
Sentiment: neutral
Topics: corporate-disclosure, sec-filing
TL;DR
Eton Pharma filed a standard 8-K, no major news.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois. The report does not contain specific financial figures or material events beyond standard corporate disclosures.
Why It Matters
This filing serves as a routine corporate disclosure, updating the SEC on Eton Pharmaceuticals' basic information and structure. It does not appear to contain new material information that would immediately impact the company's stock price.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain any new material information or significant financial events.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7278 (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Eton Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 6, 2025, serving as a routine corporate disclosure.
Where are Eton Pharmaceuticals, Inc.'s principal executive offices located?
Eton Pharmaceuticals, Inc.'s principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7278.
In which state was Eton Pharmaceuticals, Inc. incorporated?
Eton Pharmaceuticals, Inc. was incorporated in Delaware.
What is the SEC file number for Eton Pharmaceuticals, Inc.?
The SEC file number for Eton Pharmaceuticals, Inc. is 001-38738.
Does this filing indicate any specific new product launches or financial results for Eton Pharmaceuticals?
No, this filing is a current report (8-K) primarily detailing corporate information and does not specify new product launches or detailed financial results.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-02-06 06:55:20
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20250205_8k.htm (8-K) — 26KB
- ex_775326.htm (EX-99.1) — 9KB
- 0001437749-25-002935.txt ( ) — 170KB
- eton-20250206.xsd (EX-101.SCH) — 3KB
- eton-20250206_def.xml (EX-101.DEF) — 12KB
- eton-20250206_lab.xml (EX-101.LAB) — 15KB
- eton-20250206_pre.xml (EX-101.PRE) — 12KB
- eton20250205_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On February 6, 2025, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for ET-400. The new PDUFA goal date is May 28, 2025. Eton was notified that the FDA requires additional time to conduct a full review of supplemental information that was provided in December in response to an FDA request. The FDA communicated that it has applied a standard three-month extension from the original goal date of February 28, 2025. Eton believes it has fully addressed all questions and data requests from the FDA and there are no outstanding requests. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated February 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 6, 2025 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4